Evidence map›Paper›PMID 30949886›Full record

ArticleClinical and experimental nephrology2019

N-Acetyl-seryl-aspartyl-lysyl-proline is a potential biomarker of renal function in normoalbuminuric diabetic patients with eGFR ≥ 30 ml/min/1.73 m

Kyoko Nitta, Takako Nagai, Yuiko Mizunuma, Munehiro Kitada, Atsushi Nakagawa, Masaru Sakurai, Masao Toyoda, Masakazu Haneda, Keizo Kanasaki, Daisuke Koya

Abstract read
PubMed Publisher
In one paragraph

Article in Clinical and experimental nephrology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
0.6field-weighted citation impact, top 34% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 5 citations in OpenAlex.

  1. Article
  2. Epigenetic modification in diabetic kidney disease.Frontiers in endocrinology · 2023
    Review
  3. Review
  4. CD-1Journal of diabetes investigation · 2020
    Article
  5. Review
  6. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 3 institutions in 1 country.

Kyoko NittaDepartment of Diabetology and Endocrinology, Kanazawa Medical University, Uchinada, Ishikawa, 920-0293, Japan.
Takako NagaiDepartment of Diabetology and Endocrinology, Kanazawa Medical University, Uchinada, Ishikawa, 920-0293, Japan.
Yuiko MizunumaDepartment of Diabetology and Endocrinology, Kanazawa Medical University, Uchinada, Ishikawa, 920-0293, Japan.
Munehiro KitadaDepartment of Diabetology and Endocrinology, Kanazawa Medical University, Uchinada, Ishikawa, 920-0293, Japan.
Atsushi NakagawaDepartment of Diabetology and Endocrinology, Kanazawa Medical University, Uchinada, Ishikawa, 920-0293, Japan.
Masaru SakuraiDepartment of Social and Environmental Medicine, Kanazawa Medical University, Uchinada, Ishikawa, 920-0293, Japan.
Masao ToyodaInternal Medicine, Division of Nephrology and Metabolism, Tokai University School of Medicine, Isehara, Kanagawa, 259-1193, Japan.
Masakazu HanedaNishiumeda Clinic for Asian Medical Collaboration near JR Osaka Station, Maruito Nishi Umeda Building 3F, 3-3-45, Umeda Kita-ku, Osaka, 530-0001, Japan.
Keizo KanasakiDepartment of Diabetology and Endocrinology, Kanazawa Medical University, Uchinada, Ishikawa, 920-0293, Japan. kkanasak@kanazawa-med.ac.jp.
Daisuke KoyaDepartment of Diabetology and Endocrinology, Kanazawa Medical University, Uchinada, Ishikawa, 920-0293, Japan.
Kanazawa Medical University · JPOsaka Nishi Clinic · JPTokai University · JP

Funding

Japan Society for the Promotion of Science 24659264
6 · The paper itself

Abstract

backgroundA biomarker, by which we can predict alterations of renal function in normoalbuminuric diabetic patients, is not available. Here, we report that endogenous anti-fibrotic peptide N-acetyl-seryl-aspartyl-lysyl-proline (AcSDKP) represents a potential biomarker to predict alterations in eGFR in normoalbuminuric diabetic patients.

methodsWe analyzed 21 normoalbuminuric diabetic patients with eGFR ≥ 30 ml/min/1.73 m

resultsDuring ~ 4 years, the alteration in eGFR [ΔeGFR

conclusionAcSDKP represents a potentially useful biomarker to predict alterations in the renal function of patients with diabetes presenting normoalbuminuria.

Indexed as

Glomerular Filtration RateAgedBiomarkersDiabetes Mellitus, Type 2Diabetic NephropathiesEarly DiagnosisFemaleHumansKidneyMaleMiddle AgedOligopeptidesPredictive Value of TestsPrognosisTime FactorsUrinalysisBiomarkersgoralatideOligopeptidesAcSDKPBiomarkerDiabetic nephropathyDKDNormoalbuminuria

Identifiers

PMID30949886
OpenAlexW2930997593

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.